Iterative Health raises $77 million Series C to expand AI-powered clinical trial network

Iterative Health has closed a $77 million Series C financing round led by Intrepid Growth Partners and GV, with participation from EDBI and existing investors. The company's multispecialty clinical research network, spanning more than 100 sites globally, delivers 2x faster site activation and 3x higher patient enrollment compared to industry benchmarks.

Iterative Health has closed a $77 million Series C financing round led by Intrepid Growth Partners and GV (Google Ventures), joined by new investors EDBI and a family office, with participation from existing investors Insight Partners and Obvious Ventures, according to an official announcement. The company's clinical research network embeds research directly into clinical care, combining centralized operations, expert staffing, proprietary AI technology, and clinical trial expertise.

Iterative Health is a healthcare technology and services company powering clinical research acceleration. The company's global network includes more than 100 research sites across North America, Europe, India, and Australia, with partnerships with over 40 pharmaceutical, biotech, medical device, and contract research organisations. The network delivers 2x faster site activation (reducing startup timelines by up to three months) and 3x higher patient enrollment rates compared to industry benchmarks for IBD trials.

This development matters for the clinical research industry, where systematic challenges delay therapy delivery to patients. More than half of research sites enroll one or fewer patients per study, and nearly 90% of US-based trials fail to meet enrollment targets on time. The company's site-serving model addresses these constraints by placing site success at the centre of trial execution.

For the pharmaceutical and biotechnology sectors, the funding will support expansion into additional therapeutic areas including cardiology and obesity, as well as continued geographic growth. As part of the financing, Ajay Agrawal of Intrepid Growth Partners joins Iterative Health's Board of Directors, with Anthony Philippakis of GV joining as a board observer.